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OBJECTIVE—To investigate a new clinically relevant immuno-
regulatory strategy based on treatment with murine Thymoglobu-
lin mATG Genzyme and CTLA4-Ig in NOD mice to prevent allo-
and autoimmune activation using a stringent model of islet
transplantation and diabetes reversal.
RESEARCH DESIGN AND METHODS—Using allogeneic islet
transplantation models as well as NOD mice with recent onset
type 1 diabetes, we addressed the therapeutic efﬁcacy and
immunomodulatory mechanisms associated with a new immu-
noregulatory protocol based on prolonged low-dose mATG plus
CTLA4-Ig.
RESULTS—BALB/c islets transplanted into hyperglycemic NOD
mice under prolonged mATGCTLA4-Ig treatment showed a
pronounced delay in allograft rejection compared with untreated
mice (mean survival time: 54 vs. 8 days, P  0.0001). Immuno-
logic analysis of mice receiving transplants revealed a complete
abrogation of autoimmune responses and severe downregulation
of alloimmunity in response to treatment. The striking effect on
autoimmunity was conﬁrmed by 100% diabetes reversal in newly
hyperglycemic NOD mice and 100% indeﬁnite survival of synge-
neic islet transplantation (NOD.SCID into NOD mice).
CONCLUSIONS—The capacity to regulate alloimmunity and to
abrogate the autoimmune response in NOD mice in different
settings conﬁrmed that prolonged mATGCTLA4-Ig treatment is
a clinically relevant strategy to translate to humans with type 1
diabetes. Diabetes 59:2253–2264, 2010
S
uccessful islet transplantation can improve met-
abolic control and re-establish normoglycemia in
subjects with type 1 diabetes (1). Unfortunately,
transplanted islets are subject to both alloim-
mune responses and the recurrence of autoimmunity;
either of which, when left uncontrolled, is capable of
jeopardizing long-term islet function (1–4). Nonobese di-
abetic (NOD) mice represent the most commonly used
animal model for human type 1 diabetes, and when used in
settings of islet transplantation, the results obtained can
be used to predict the results in type 1 diabetic patients
(5–9). Indeed, several of the immunoregulatory defects
observed in type 1 diabetic patients parallel those in NOD
mice (10).
Thymoglobulin (ATG), a widely used induction therapy
in solid organ transplantation (11), as well as in islet
transplantation (12–14), depletes peripheral T cells and
inhibits T-effector cell (Teff) expansion, but spares T
regulatory cells (Treg) (15). ATG may be used for this
purpose in immunoregulatory protocols. Moreover, mu-
rine ATG (mATG), similar to other depleting agents with
immunoregulatory function (9), has been shown to be
effective in downregulating the autoimmune response and
in providing therapeutic efﬁcacy in terms of preventing
and reverting type 1 diabetes in NOD mice (16,17); mATG
was recently shown to be particularly effective when
combined with granulocyte colony-stimulating factor ther-
apy (18). We have used a new mATG-based protocol in
which low chronic doses were administered to continually
promote Treg expansion and maintain low numbers of
Teffs. A major issue when using T-cell–depleting strate-
gies, such as ATG, in the clinical setting is the robust
proliferation of residual or new emerging lymphocytes in
the process of homeostatic proliferation (19), which can
create a barrier to tolerance induction because re-emerg-
ing lymphocytes typically have an activated phenotype and
are more resistant to regulation compared with naïve cells
(19). In this regard, CD28, which is expressed constitu-
tively on T cells and ligates either B7-1 (CD80) or B7-2
(CD86) on antigen-presenting cells (APC), thus resulting in
delivery of signals that promote clonal expansion and the
effector function of T cells (20,21), may play a pivotal role
in regulating homeostatic proliferation (19). Targeting
CD28 signaling may thus be an effective strategy to control
homeostatic proliferation during T-cell depletion. The
most widely used reagent to target CD28-CD80/CD86
costimulation is CTLA4-Ig, a fusion protein modeled on
the structure of CTLA4 (22). CTLA4 is a coinhibitory
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the T-cell response after CD80/CD86 engagement (23,24).
Moreover, because the afﬁnity for CD80/CD86 is greater in
CTLA4 than CD28, the use of CTLA4-Ig prevents CD28
engagement on T cells and thus prevents T-cell activation
(20). CTLA4-Ig is currently used in clinical settings for the
treatment of autoimmune disorders (25–27).
Based on this information, we hypothesized that com-
bining short-term CTLA4-Ig treatment with prolonged low-
dose mATG could prevent the homeostatic proliferation
that follows mATG treatment, as well as synergizing with
mATG to downregulate the allo- and autoimmune re-
sponses, thereby promoting both islet allograft survival
and reversal of type 1 diabetes.
RESEARCH DESIGN AND METHODS
Mice. Female NOD and NOD.SCID mice, as well as BALB/c mice, were
obtained from Jackson Laboratory (Bar Harbor, ME). All mice were cared for
in accordance with institutional guidelines under speciﬁc-pathogen–free con-
ditions at the Harvard Medical School Facilities for Animal Care and Housing.
Protocols were approved by the Institutional Animal Care and Use Committee.
Monitoring for diabetes. Blood glucose was measured using Accu-Check
Advantage glucometers (Roche Diagnostics, Indianapolis, IN). The diabetes
reversal protocol was tested in newly hyperglycemic mice after 2 consecutive
days of blood glucose 250 mg/dl. Stable reversal of diabetes was assessed
with blood glucose measurements twice weekly.
Insulitis score. Insulitis scoring was performed on hematoxylin and eosin
(H&E)-stained pancreatic sections. A score of 0 to 4 was assigned based on
islet inﬁltration by an experienced pathologist, as previously described (7).
Insulitis scores were graded as follows: grade 0, normal islets; grade 1, mild
mononuclear inﬁltration (25%) at the periphery; grade 2, 25–50% of the islets
inﬁltrated; grade 3, 50% of the islets inﬁltrated; grade 4, islets completely
inﬁltrated with no residual parenchyma remaining. At least 30 islets per group
were analyzed and pooled from sections obtained from different mice.
Islet inﬁltration score. A score from 0 to 4 was assigned to graft islets based
on grade of inﬁltration and islet preservation. Grade 0  no inﬂammation;
grade 1  peri-islet inﬂammation only; grade 2  intra-islet inﬂammation
occupying 50% of the islets; grade 3  intra-islet inﬂammation occupying
50% of the islets; grade 4  complete or near complete obliteration of islets
by inﬂammation.
Isolation of pancreatic islets. Pancreatic islets were isolated by collage-
nase digestion followed by Histopaque 1077 (Sigma Chemical Co., St. Louis,
MO) density gradient separation and hand-picking, as described previously
(28).
Islet transplantation. NOD mice were allowed to develop diabetes sponta-
neously, and 800 islets from BALB/c donors (fully allogeneic) or NOD.SCID
donors (syngeneic) were transplanted under the renal capsule. Once normo-
glycemia was achieved, graft rejection was deﬁned on the basis of stable blood
glucose levels of 250 mg/dl.
Cardiac transplantation. Heart transplantation was performed in NOD mice
as described previously (29) to compare the rejection of islet allografts with
the rejection of nonautoimmune subjected grafts. Cardiac graft survival was
assessed by palpation. Islet and cardiac grafting procedures were performed
independently.
Skin transplantation. Full-thickness trunk skin grafts (1 cm
2) harvested
from BALB/c donors were transplanted onto the ﬂank of NOD.SCID recipient
mice, sutured with 6.0 silk, and secured with dry gauze and a bandage for 7
days. Skin graft survival was monitored daily thereafter, and rejection was
deﬁned as complete graft necrosis.
Antibodies and treatment protocol. Murine ATG (mATG) or control Ig
were administered as follows: 1) induction mATG (500 g on days 0 and 4);
2) CTLA4-Ig (500 g on day 0; 250 g on days 2, 4, 6, 8, and 10); 3) prolonged
mATG (500 g on days 0 and 4; 100 g twice weekly starting on day 10);
4) induction mATGCTLA4-Ig (mATG: 500 g on days 0 and 4  CTLA4-Ig:
500 g on day 0; 250 g on days 2, 4, 6, 8, and 10); or 5) prolonged
mATGCTLA4-Ig (mATG: 500 g on days 0 and day 4, then twice weekly
starting at day 10  CTLA4-Ig: 500 g on day 0; 250 g at days 2, 4, 6, 8, and
10).
Islet pathology and immunohistochemistry. Transplanted mice were
killed at various time points to obtain histology specimens. Kidney sections
were stained with H&E. Immunohistochemistry was performed using 5-m–
thick formalin-ﬁxed, parafﬁn-embedded tissue sections as previously de-
scribed (7). FoxP3
 percentage on CD3
 cells was assessed using a Aperio
ScanScope. Brieﬂy, stained slides were scanned at 200 magniﬁcation using
an Aperio ScanScope XT workstation (Aperio Technology, Vista, CA). Images
were visualized and annotated using ImageScope software (version
10.0.35.1800, Aperio Technology) and were analyzed using a standard analysis
algorithm (color deconvolution v9.0, Aperio Technology).
Flow cytometry (ﬂuorescence-activated cell sorter). Rat anti-mouse
CD19 PE, CD20 PE, CD22 PE, B220 PE, B220 PerCP, CD80 (B7-1) PE, CD86
(B7-2) PE, H-2
d FITC, CD4 FITC, CD23 FITC, CD25 PE, CD44 PE, CD45 FITC,
CD62L APC, CD93 PE (C1qRp), and IgM PAPC were purchased from BD
Biosciences (San Jose, CA) and eBiosciences (San Diego, CA). FoxP3 APC
was purchased from eBiosciences. Cells recovered from spleen and peripheral
blood were subjected to ﬂuorescence-activated cell sorter analysis and run on
a FACSCalibur (Becton Dickinson). Data were analyzed using FlowJo soft-
ware version 6.3.2 (Treestar, Ashland, OR). FoxP3 analysis was performed
after overnight permeabilization of cells extracted from spleen and peripheral
lymphoid tissue using commercially available antibodies and gating on
CD4
CD25
 cells.
Enzyme-linked immunosorbent spot. To measure cytokine production by
splenocytes extracted from different groups of NOD mice, our enzyme-linked
immunosorbent spot (ELISPOT) assay was used as previously described (4).
Brieﬂy, Millipore immunospot plates (Millipore Corporation, Bedford, MA)
were coated with capture antibodies (BD Biosciences). Plates were blocked
with 1% BSA to prevent nonspeciﬁc binding. NOD splenocytes (1  10
6) were
challenged in the presence of 150 g/ml BDC2.5 peptide (Ac-RTRPLWVRME
amide, QCB, Hopkinton MA), 50 g/ml IGRP
(206–214) peptide (VYLKTNVFL) or
1  10
6 BALB/C irradiated splenocytes. After 2 days of culture in 10% FCS, 1%
penicillin-streptomycin RPMI at 37°C and 5% CO2, plates were washed and
biotinylated antibodies speciﬁc for each cytokine were added to the wells,
followed by incubation at 4°C for 12 h. Plates were then washed, incubated at
room temperature with streptavidin-horseradish peroxidase (HRP) for 2 h,
and developed using aminoethyl carbazole (AEC, Sigma Aldrich) diluted in
N,N-dimethylformamide. Spots were counted on an immunospot analyzer
(Cellular Technology, Cleveland, OH).
In vivo proliferation. A quantity of 50  10
6 Carboxyﬂuoroscein-succinimidyl-
ester (CFSE)-labeled lymphocytes from NOD mice were injected intravenously
into NOD.SCID mice in 0.5 ml of sterile PBS. Recipients were treated according
to standard protocols. Spleens were harvested 3 days after adoptive transfer. The
proliferation of CFSE-labeled donor cells in the recipient spleen was examined by
ﬂow cytometry based on CFSE dilution analysis. In particular, proliferation of
CD4
 (using anti-CD4 APC) and CD8
 (using anti-CD8 APC) cells was assessed.
Ovalbumin immunization. Ovalbumin peptide (Sigma Aldrich) emulsiﬁed in
complete Freund’s adjuvant (Sigma Aldrich) was injected once (100 g/mouse
i.p.) in naïve or transplanted NOD mice. Splenocytes were collected and used
in in vitro assays after rechallenge with 1 mol/l ovalbumin peptide for 24 h.
Luminex serum cytokine determination. Treated or control NOD mice
were bled via tail perforation on days 0, 7, 14, and 28 after islet transplanta-
tion, and serum samples were collected. The BeadLyte Mouse Multi-Cytokine
Beadmaster Kit (Millipore) was used according to the manufacturer’s protocol
to determine cytokine levels of IL-1, IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9,
IL-10, IL-12p70, IL-15, IL-17, IFN-	, and TNF-. Brieﬂy, supernatant samples
were incubated overnight at room temperature with beads conjugated to the
aforementioned cytokines, matched biotinylated reporters were added and
incubated for 1.5 h, and streptavidin-phycoerythrin solution was incubated
with samples for 30 min. After the addition of stop solution, sample cytokine
levels were calculated from a standard curve using a Luminex100 reader
(Luminex Corporation, Austin, TX).
Adoptive transfer studies. Skin grafts from BALB/c donors were trans-
planted onto immunodeﬁcient NOD.SCID hosts. Splenocytes (15  10
6) from
transplanted NOD mice treated with prolonged mATGCTLA4-Ig at day 56 or
from untransplanted NOD mice were adoptively transferred into NOD.SCID
that received skin transplantation. These NOD.SCID mice were monitored for
the onset of hyperglycemia and skin graft rejection.
Statistical analyses. Data are expressed as mean 
 SE. Kaplan-Meier
analysis was used for survival analysis. ANOVA (for parametric data) and
Kruskal-Walliss (for nonparametric data) were also used. When the two
groups were compared cross-sectionally, the two-sided unpaired Student t
test (for parametric data) or the Mann-Whitney test (for nonparametric data)
was used according to value distribution. A P value  0.05 (by two-tailed
testing) was considered an indicator of statistical signiﬁcance. Analyses of
data were performed using a SPSS statistical package for Windows (SPSS,
Chicago, IL).
RESULTS
mATG depletes T-lymphocytes in islet-transplanted
NOD mice. We tested the depleting potential of mATG on
peripheral blood in an allogeneic fully mismatched model
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into NOD mice). Mice were followed until rejection, as
after rejection mice became lymphopenic and immuno-
compromised. In untreated mice, the numbers of periph-
eral CD3
 cells dropped soon after islet transplantation
(Fig. 1A). An induction dose of mATG (500 g at days 0
and 4) further depleted CD3
 cells in the peripheral blood
of NOD transplanted mice (Fig. 1A), and CD4
 and CD8

cells appeared to be equally affected (Fig. 1B and C).
Prolonged mATG treatment (mATG 500 g at days 0 and 4,
then 100 g twice weekly) did not appear to result in
further depletion.
Addition of CTLA4-Ig treatment (500 g at day 0 and 250
g at days 2, 4, 6, 8, and 10) slowed T-cell reconstitution
(Fig. 1A). At day 28, the T-cell pool in the induction group
treated with mATGCTLA4-Ig had been replenished
enough to appear similar to the T-cell pool in the pro-
longed mATGCTLA4-Ig group (P  NS) (Fig. 1A).
We then analyzed the percentages of CD4
CD25

FoxP3
 (Treg) and CD4
CD44
CD62
low (Teff) cells. Pro-
longed mATG treatment increased the peripheral Treg
percentage at days 7 and 14 compared with untreated
mice. At day 7 only, in the induction mATG group, the Treg
percentage also increased (Fig. 1D). Combining CTLA4-Ig
with mATG inhibited the increase in Treg percentage
produced by the mATG treatment during both induction
and prolonged mATG treatment (Fig. 1D). Notably, at day
28, the percentage of Tregs was higher in the prolonged
mATGCTLA4-Ig group compared with the induction
mATGCTLA4-Ig group (Fig. 1D).
Induction mATG treatment per se did not have any
effect on Teff percentage; however, prolonged mATG
treatment increased Teff cells at day 14 (Fig. 1E), whereas
the combination of mATG and CTLA4-Ig reduced the
percentage of Teff cells (Fig. 1E). At day 28, Teff percent-
ages were higher in the prolonged mATGCTLA4-Ig group
compared with the induction mATGCTLA4-Ig animals
(Fig. 1E).
Prolonged mATGCTLA4-Ig treatment expands
splenic Tregs and controls Teff proliferation. We
conﬁrmed the effect of induction mATG, induction
mATGCTLA4-Ig, and prolonged mATGCTLA4-Ig on
Treg and Teff balance in the mouse spleen. At day 14,
mATG induction increased the Treg percentage in the
spleen compared with hyperglycemic untransplanted mice
(i.e., hyper) (Fig. 2A). Teff percentage was also increased
by induction mATG (Fig. 2B). The combination of mATG
and CTLA4-Ig did not signiﬁcantly affect the Treg percent-
age compared with induction mATG treatment alone (Fig.
2A), but signiﬁcantly reduced Teffs (Fig. 2B). We then
compared the effect of prolonged mATG treatment to
induction mATG, both combined with CTLA4-Ig, at day 28.
Prolonged mATG treatment signiﬁcantly increased Tregs
compared with induction mATG (Tregs, shown as percent-
ages of the CD4
 population, on day 28: prolonged
mATGCTLA4-Ig 19.5 
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FIG. 1. Analysis of Peripheral Blood Mononuclear Cells (PBMC) was performed at various time points after transplantation in diabetic NOD mice.
CD4
 and CD8
 T-cell depletion is detected on day 7 after mATG treatment (untreated vs. all treatment, P < 0.05) (A–C). Addition of CTLA4-Ig
slowed reconstitution after mATG depletion on day 14 (CD3
, CD4
, and CD8
 cells: prolonged mATGCTLA4-Ig vs. prolonged mATG, P < 0.05).
On day 28, peripheral T-cell percentage in animals treated with prolonged mATGCTLA4-Ig was similar to that of animals treated with induction
mATGCTLA4-Ig (P  NS). On day 7, FoxP3
CD25
CD4
 (Tregs) was increased by both induction and prolonged mATG treatment (P < 0.05
vs. day 7 untreated), and on day 14 by prolonged mATG treatment (P < 0.05 vs. day 7 untreated) (D). Addition of CTLA4-Ig abrogated this
increase (day 7: induction mATGCTLA4-Ig vs. induction mATG, P  0.04; day 7 and day 14 prolonged mATGCTLA4-Ig vs. prolonged mATG,
P  0.002 and P  0.008, respectively) (D). Peripheral Treg frequency at day 28 was increased with prolonged mATG  CTLA4-Ig treatment
compared with induction mATGCTLA4-Ig treatment (P < 0.05) (D). On day 14, a relative increase in CD44
highCD62
lowCD4
 cells (Teffs) was
evident with prolonged mATG treatment (P < 0.05 vs. day 7 untreated); this increase was prevented by the addition of CTLA4-Ig (prolonged
mATGCTLA4-Ig vs. prolonged mATG, P  0.0001) (E). On day 28, Teffs were increased in the prolonged mATGCTLA4-Ig group compared with
the induction group (P < 0.05) (E). *P < 0.05.
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 0.9%, n  3, P  0.04) (Fig. 2A); however,
there was no signiﬁcant difference in Teff cells (Fig. 2B).
Tregs and Teffs were also analyzed in transplanted islet-
draining lymph nodes, conﬁrming the pattern observed in
the spleen (Fig. 2A and B). These data together showed
that prolonged low-dose mATG treatment, compared with
induction mATG treatment, is capable of tipping the
Treg/Teff balance to favor Treg.
CTLA4-Ig treatment reduces the homeostatic prolif-
eration that follows mATG depletion. Homeostatic
proliferation is considered a barrier to tolerance. To
evaluate the effectiveness of our approach (mATGCTLA4-Ig)
to blunt homeostatic proliferation, we performed adoptive
transfer experiments. NOD splenocytes (50  10
6) were
labeled with CFSE and transferred into treated-NOD.SCID
mice. Three days after adoptive transfer, splenocytes were
harvested and the percentage of nondividing T cells
(CD4
/CD8
 CFSE
high) was assessed as a parameter of
homeostatic proliferation (19). The number of nondividing
T cells was decreased in mATG-treated mice compared
with untreated mice, conﬁrming the existence of post-
depletion homeostatic proliferation upon mATG treat-
ment. However, the combination of mATG and CTLA4-Ig
reduced homeostatic proliferation, with an increase in the
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FIG. 2. Splenocytes and islet graft draining lymph nodes were analyzed at various time points in treated and control mice. Treg
(CD4
CD25
Foxp3
 cells) frequency was stable after mATG treatment on day 7 (A1) and increased at day 14 (P < 0.05 vs. hyper) (A2). The
combination with CTLA4-Ig on day 14 appeared not to inhibit Treg percentage increase (P < 0.05 vs. hyper) (A2). On day 28, the Treg proportion
was higher in the prolonged mATGCTLA4-Ig group compared with the induction group (P < 0.05) (A3). A similar increased proportion, although
the difference did not reach statistical signiﬁcance, was seen in graft draining lymph nodes on days 7 (A4) and 28 (A5). Teff (CD4
CD44
hiCD62
low)
percentage in the spleen was shown to be stable on day 7 after transplantation (B1), but Teffs were increased after mATG treatment on day 14
(P < 0.05 vs. hyper) (B2); its combination with CTLA4-Ig completely prevented any Teff increase, (B2). On day 28, Teff cell proportions in
prolonged and induction mATGCTLA4-Ig-treated mice were similar (B3). A similar proﬁle was observed in graft draining lymph nodes on days
7( B4) and 28 (B5). Splenocytes (50  10
6) were CFSE-labeled and adoptively transferred into NOD.SCID mice treated using a standard protocol.
mATG-treated mice showed a reduced percentage of CFSE
high-undividing CD8
 and CD4
 cells (P < 0.05 vs. untreated), revealing postmATG
depletion homeostatic proliferation (C1 and 2). On the contrary, combination with CTLA4-Ig reverted (completely [CD8
 cells] or partially
[CD4
 cells]) the reduction in undividing cells percentage after mATG treatment (C1 and 2). *P < 0.05.
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homeostatic proliferation was more evident in CD8
 T
cells, although it was partially effective in CD4
 T cells.
Taken together, these data reveal the capacity of CTLA4-Ig
for inhibiting mATG-induced homeostatic proliferation,
providing an appealing combination therapy for a novel
immunomodulatory approach. We also tested whether the
activation of dendritic cells (DCs) is inﬂuenced by
CTLA4-Ig treatment. Hyperglycemic mice were trans-
planted with allogeneic islets and either treated with
anti-CTLA4-Ig or left untreated. No major differences were
observed with regard to costimulatory molecule expres-
sion in DCs obtained from the two groups at day 7 after
transplantation (data not shown).
Prolonged mATG treatment synergizes with CTLA4-Ig
to prolong islet allograft survival in spontaneously
diabetic NOD mice. We then compared the impact of
mATG treatment alone or combined with CTLA4-Ig on
islet allograft survival. Untreated NOD mice invariably
rejected allografts (untreated: mean survival time [MST] of
8 days, n  5). We then tested mATG as a single agent.
Considering the potential of mATG treatment to cause
reversal in newly hyperglycemic NOD mice (16), NOD
mice were used as islet recipients after at least 14 consec-
utive days of glucose measurements 400 mg/dl. The
mATG induction extended allograft survival (induction
mATG: MST of 16.5 days, n  10, P  0.0001 vs. untreated)
(Fig. 3A). Prolonged mATG treatment per se did not
further increase graft survival (prolonged mATG: MST of
14 days, n  5, NS vs. induction mATG) (Fig. 3A) with 1 of
5 mice reaching 40 days of survival. We therefore com-
bined mATG with CTLA4-Ig, with the goal of reducing
activation of the immune system in response to alloantigen
and to counteract homeostatic proliferation, which fol-
lows T-cell depletion. CTLA4-Ig alone slightly prolonged
graft survival (CTLA4-Ig: MST of 12.5 days, n  4, P  0.04
vs. control) (Fig. 3A) and synergized with mATG to further
increase allograft survival (induction mATGCTLA4-Ig:
MST of 32 days, n  9, P  0.0001 vs. induction mATG)
(Fig. 3A). Finally, the combination of prolonged mATG
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FIG. 3. BALB/c islets were transplanted into hyperglycemic NOD mice, and allograft survival was evaluated. All treatments signiﬁcantly prolonged
graft survival (P < 0.05 vs. untreated). The addition of CTLA4-Ig synergized with mATG treatment to delay rejection (graft survival: induction
mATG vs. induction mATGCTLA4-Ig, P < 0.05; prolonged mATG vs. prolonged mATGCTLA4-Ig, *P < 0.05) (A). Prolonged mATGCTLA4-Ig
was shown to be more efﬁcacious than induction mATGCTLA4-Ig (**P < 0.05) (A). Immunocompetence was examined in prolonged
mATGCTLA4-Ig treated mice via evaluation of the capacity to mount an ovalbumin-speciﬁc response. The IFN- (B1)- and IL-4 (B2)-speciﬁc
responses were higher in mice immunized during treatment compared with unimmunized untreated mice (*P < 0.05). Serum samples were
collected after islet transplantation on days 7, 14, and 28, and peripheral cytokine proﬁle was evaluated. The Th1-related cytokines (IFN-, IL-2)
were increased by mATG treatment (P < 0.05 vs. hyper), whereas this increase was prevented by mATG combination with CTLA4-Ig (C). A similar
pattern was observed for the immunoregulatory cytokine IL-10 and for the cytokines related to homeostatic proliferation (IL-7, IL-15) (C). The
proinﬂammatory cytokine IL-6 increased after transplantation (P < 0.05 vs. hyper), whereas treatment with mATG completely prevented this
increase (C). IL-1 and the Th2 cytokine IL-5 were not signiﬁcantly affected (C).
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vival (prolonged ATGCTLA4-Ig: MST of 54 days, n  10,
P  0.007 vs. mATGCTLA4) (Fig. 3A). Notably, in this
stringent model of enhanced allo-/auto-immune responses,
30% of these mice retained graft function for more then 70
days. We also tested whether depletion of Tregs through
treatment with anti-CD25-Ig at the time of transplantation
(500 g at days 6 and 1) was able to abrogate the effect
of prolonged mATGCTLA4-Ig. Although CD25-depleted
untreated NOD mice rejected islet grafts rapidly (MST of 8
days), CD25-depleted NOD mice treated with prolonged
mATGCTLA4 showed a prolongation of islet graft sur-
vival (MST of 53 days), suggesting the capacity of our
approach to reconstitute the Treg pool (data not shown).
Prolonged mATGCTLA4-Ig treatment has little ef-
fect on immunocompetence. We then evaluated whether
immunocompetence was preserved during prolonged
mATGCTLA4-Ig treatment. We assessed the ability of
treated mice to mount an antigen-speciﬁc response. Pro-
longed mATGCTLA4-Ig-treated and untreated NOD mice
were immunized at day 28 with ovalbumin. After 3 days,
splenocytes were harvested and rechallenged in vitro with
ovalbumin.
Modest IFN-	 and IL-4 production was seen after in vitro
rechallenge in unimmunized mice independent of the
treatment (unimmunized: IFN-	79 
 7, IL-4  6 
 3,
measured as cytokine-producing cells, n  3). On the
contrary, markedly high IFN-	 and IL-4 production was
observed in immunized mice. No differences were seen
between mice immunized during treatment and immu-
nized untreated mice with regard to IL-4 production (im-
munized during treatment  108 
 15 vs. immunized
untreated  95 
 26, n  3, P  NS). Only a slight
reduction was noted in IFN-	 production (immunized
during treatment  347 
 17 vs. immunized untreated 
468 
 11, n  3, P  0.01) (Fig. 3B2). These data suggest
that the ability of mounting an antigen-speciﬁc response is
only slightly affected during treatment.
Prolonged mATG and CTLA4-Ig combination treat-
ment reshapes the peripheral cytokine proﬁle. We
then evaluated the effect of the treatments above on
peripheral cytokine proﬁles using the Luminex assay.
After transplantation, Th1 cytokines (IFN-	 and IL-2)
appeared to be increased in the induction mATG group
compared with hyperglycemic untransplanted mice (hy-
per) (Fig. 3C). Adding CTLA4-Ig to the induction mATG
induction therapy completely prevented an increase in Th1
peripheral cytokines (Fig. 3C). CTLA4-Ig treatment also
abrogated production of Th1 cytokines in the prolonged
mATGCTLA4-Ig group at early time points (days 7 and
14), whereas there was an increase in Th1 cytokines
observed later (Fig. 3C). The Th2 cytokine IL-4 was found
to be poorly expressed (data not shown), whereas IL-5 and
IL-13 did not demonstrate clear Th2 activation after mATG
treatment (Fig. 3C). The increase in the proinﬂammatory
cytokine IL-6, evident after islet transplantation in un-
treated mice, seemed to be controlled in mATG-treated
mice regardless of the use of CTLA4-Ig (Fig. 3C). After
depletion, the remaining cells enter a proliferation phase,
which tends to repopulate the T-cell niche during homeo-
static proliferation. Although several cytokines are in-
volved in this process, IL-7 and IL-15 are central (30,31).
After mATG treatment, these two cytokines rapidly in-
creased in their concentration (Fig. 3C), whereas combi-
nation treatment with CTLA4-Ig maintained levels of both
cytokines (Fig. 3C), which may explain the moderate
recovery curve in CTLA4-Ig-treated mice and may also
cause a lower state of activation of proliferating T cells.
IL-10, a Treg-associated cytokine, increased after induc-
tion mATG (Fig. 3C); however, concomitant treatment
with CTLA4-Ig prevented the increase (Fig. 3C). At day 28
in prolonged mATGCTLA4-Ig-treated mice, IL-10 levels
were increased (Fig. 3C), whereas IL-17 was almost unde-
tectable (Fig. 3C).
Prolonged mATGCTLA4-Ig treatment preserves is-
let morphology. Grafts were analyzed at signiﬁcant time
points, and immune cells inﬁltration was blinded quanti-
ﬁed by a pathologist (S.R.) with islet inﬁltration score (IIS)
grading from 0 (no inﬁltration, preserved islets) to 4
(massive inﬁltration, no islet preservation, signs of ﬁbro-
sis). H&E staining in untreated mice showed that islets
were inﬁltrated by CD3
 and B220
 cells throughout the
graft 7 days after transplantation; islet architecture was
lost, with only a few remaining insulin-positive cells,
IIS:three (Fig. 4A). The percentage of FoxP3 on CD3
 cells
was then assessed using a Aperio ScanScope; only a small
proportion of CD3
 cells appeared to be FoxP3-positive
(11%). In the induction mATG group, islet morphology was
preserved with positive insulin staining, whereas immuno-
staining showed a mild extra-islet CD3
/B220
 inﬁltrate,
(IIS:1), with an increased proportion of Tregs (FoxP3
 in
CD3
 cells: 25%) (Fig. 4B). This reduced islet inﬁltration
was also detected in the mATGCTLA4-Ig group at day 7,
IIS:0; FoxP3
 in CD3
 cells: 28% (Fig. 4C). When mATG
was discontinued, a massive inﬁltrate composed of CD3

and B220
 cells was observed throughout the graft area by
day 28, with few insulin-positive cells remaining (IIS:3–4)
and a reduced proportion of Tregs (FoxP3
 in CD3
 cells:
17%) (Fig. 4D). In the prolonged mATGCTLA4-Ig group,
islet morphology was well preserved (with insulin staining
still detectable), with lymphocyte inﬁltrate consisting of
predominantly B cells surrounding, but not inﬁltrating, the
islets (IIS:1), whereas Treg numbers were increased
(FoxP3
 in CD3
 cells: 23%) (Fig. 4E).
Prolonged mATGCTLA4-Ig treatment reduces re-
sponses to allo- and autoantigen ex vivo. To determine
the relative contributions of auto- and alloimmune re-
sponses in the rejection process, we tested the potential
for those responses in NOD mice treated with different
regimens. Splenocytes isolated from mice receiving the
various treatments were challenged in an ELISPOT assay
with 1  10
6 irradiated BALB/c splenocytes to assess the
veracity of alloimmune response or with 150 g/ml
BDC2.5 peptide (an islet-derived peptide) to assess the
autoimmune response, and IFN-	/IL-4 production was
analyzed. At day 7 after islet transplantation, untreated
mice showed considerable IFN-	 production in response
to alloantigen; this response was highly suppressed in the
mATGCTLA4 group (IFN-	 day 7: untreated 367.3 

160.0 vs. mATGCTLA4-Ig 14 
 5, n  3 vs. 4, P  0.04;
IL-4 day 7: 91 
 8 vs. 18 
 17, respectively, n  3, P 
0.02). An intermediate response was seen in mATG-treated
mice (Fig. 5A1). At day 14, mATGCTLA4 treatment was
clearly more effective than mATG, as shown by reduced
IFN-	 production in the alloimmune assay (IFN-	 day 14:
mATGCTLA4-Ig 135 
 44 vs. mATG 354 
 27, n  3, P 
0.03) (Fig. 5A2). IL-4 production did not differ between the
two groups (data not shown). We next compared the effect
of prolonged versus induction mATG treatment combined
with CTLA4-Ig at day 28. An alloimmune assay showed
that prolonged mATG treatment suppressed IFN-	 produc-
tion compared with induction mATG (IFN-	: prolonged
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 12 vs. induction mATGCTLA4-Ig,
314 
 39, n  3, P  0.01) (Fig. 5A3).
The autoimmune response was suppressed at day 7 with
regard to IFN-	 production in response to BDC2.5 peptide
after mATG or mATGCTLA4 treatment. The IFN-	 re-
sponse was similar to that observed in normoglycemic
untransplanted NOD (normo), whereas hyperglycemic un-
transplanted NOD (hyper) mice showed a higher response
(IFN-	 day 7: mATG 39 
 28, n  3; mATGCTLA4 6 
 5,
n  2 vs. normo 16 
 3, n  5, P  NS; mATG and
mATGCTLA4-Ig vs. hyper 123 
 23, n  4, NS and P 
0.015, respectively) (Fig. 5B1). The IL-4 response was
similarly reduced (data not shown). At day 14, the auto-
immune response was suppressed in the mATGCTLA4-Ig
group, but not in the mATG group (IFN-	: mATGCTLA4-Ig
18 
 8, n  3 vs. normo, P  NS; mATG 78 
 33, n  3 vs.
normo, P  0.02) (Fig. 5B2).
The autoimmune response appeared to be attenuated by
either prolonged or induction mATGCTLA4-Ig treatment at
day 28 (IFN-	: prolonged mATGCTLA4-Ig and induction
mATGCTLA4-Ig vs. normo, P  NS) (Fig. 5B3); in terms of
the IL-4 response, no differences were observed between
prolonged or induction mATG treatmentCTLA4-Ig in re-
sponse to allo- or autoantigens (data not shown).
Collectively, these data demonstrate that mATG and
mATGCTLA4 treatment prevents alloimmune activation
and reversion of autoimmune status at day 7. Activation of
the alloimmune and autoimmune responses at days 7 and
14 may explain rejection in the untreated group and
mATG-treated group, respectively. However, activation of
alloimmunity seems to occur during islet rejection only in
induction mATGCTLA4-Ig treatment.
Interestingly, despite rejection, both allo- and autoim-
mune responses are controlled at day 56 in prolonged
mATGCTLA4-Ig-treated mice (Fig. 5A4–B4). To further
challenge the allo- and autoimmune response potential in
these animals, we performed crucial adoptive transfer
experiments. BALB/c skin transplants were performed in
NOD.SCID recipients, and 15  10
6 NOD splenocytes from
prolonged mATGCTLA4-Ig-treated mice at day 56 or
from untransplanted mice were injected intraperitoneally
the next day. To evaluate the transfer of alloimmunity,
mice were followed for skin rejection; to evaluate the
transfer of autoimmunity, the onset of diabetes was as-
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FIG. 4. Islets were transplanted under the kidney capsule of hyperglycemic NOD mice and retrieved for histologic analysis. At day 7, untreated
mice showed massive inﬁltrate with completely disrupted islet architecture (A1). Few insulin-positive cells (A2) were found in the graft. B220

(A3) and CD3
 (A4) cells were equally represented in the inﬁltrate, but FoxP3
 cells were scarcely represented (A5), as conﬁrmed by Aperio
ScanScope quantiﬁcation. A different pattern is apparent at day 7, both in mATG- and mATGCTLA4-Ig-treated mice (B and C). Islet
architecture was preserved with a mild inﬁltrate (B1 and C1), and insulin (B and C2) staining was clearly preserved. Few B220
 (B3) and CD3

(B4) cells in equal proportions could be found in mATG-treated mice; few FoxP3
 cells were present in the graft (B5). In the mATGCTLA4-
Ig-treated group, the inﬁltrate was almost absent (C3 and 4). Some of the CD3
 cells also appeared to be FoxP3
 (C5). A massive organized
inﬁltrate in the graft area was found in the induction mATGCTLA4-Ig-treated group at day 28 with no evidence of any islet allograft remaining
(D1). Insulin staining appeared weak and limited to very few cells (D2). CD3
 and B220
 cells were equally represented (D3 and 4) with very
few FoxP3
 cells (D5). In mice treated with prolonged mATGCTLA4-Ig, islet structure was preserved at day 28; inﬁltrate surrounds but does
not inﬁltrate the islets (E1). Insulin-positive cells are well represented (E2). More B220
 cells than CD3
 were represented in the inﬁltrate
(E4); notably, a higher proportion of CD3
 cells appeared to be FoxP3
 (E5). At day 80 after transplantation, in the prolonged mATGCTLA4-Ig
group, islet morphology remained preserved with massive inﬁltrate around but not inﬁltrating the islets (F1), and insulin staining was well
preserved (F2). B220
 cells appeared more abundant in the inﬁltrate than T cells (F3), as very few CD3
 cells were evident (F4). Several FoxP3

cells were present in the inﬁltrate (F5). (A high-quality digital representation of this ﬁgure is available in the online issue.)
A. VERGANI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, SEPTEMBER 2010 2259sessed. When splenocytes derived from untransplanted
mice, either hyperglycemic or normoglycemic, were adop-
tively transferred, skin was promptly rejected (MST
BALB/c skin: hyper, 13 days, and normo, 23 days, n  4,
P  0.0067), and diabetes was transferred (diabetes onset:
hyper 23 days; normo 49 days, n  5, P  0.0067) (Fig. 6A
and B). When splenocytes obtained from prolonged
mATGCTLA4-Ig-treated mice (either hyperglycemic or
normoglycemic) were adoptively transferred, skin rejec-
tion was signiﬁcantly delayed; this was particularly evi-
dent when splenocytes were derived from normoglycemic
mice (MST BALB/c skin: normoglycemic prolonged
mATGCTLA4 35 days, n  5, P  0.0067 vs. normo;
hyperglycemic prolonged mATGCTLA4-Ig 25 days, n 
4, P  0.0011 vs. hyper) (Fig. 6A). Notably, when skin
grafts from C57BL/6 mice, a 3rd party strain, were trans-
planted into NOD.SCID mice receiving adoptively transferred
splenocytes from treated or untreated normoglycemic NOD
mice, no signiﬁcant differences were observed in graft sur-
vival (MST C57BL/6 skin: normo 23 days; normoglycemic
prolonged mATGCTLA4 29 days, n  5, P  NS). More-
over, the adoptive transfer of splenocytes from either hyper-
or normoglycemic treated mice did not cause diabetes onset
in NOD.SCID mice (Fig. 6B).
Prolonged mATGCTLA4-Ig treatment completely
abrogates the autoimmune response and downregu-
lates the alloimmune response. Although it is clear that
splenocytes obtained from prolonged mATGCTLA4-Ig-
treated mice retain the potential to generate an alloim-
mune response in the adoptive transfer experiment, it
remained unclear whether this effect was related to the
suspension of treatment after adoptive transfer. To deter-
mine whether the alloimmune response could develop
during treatment, we established a model of allogeneic
heart transplantation. BALB/c hearts were transplanted
into the abdominal cavity of NOD mice, and rejection was
assessed through heart pulsation monitoring. Control mice
rapidly rejected the graft (MST of 11 days, n  2), whereas
a signiﬁcant delay, but not indeﬁnite survival, was elicited
by prolonged mATGCTLA4-Ig treatment (MST of 42
days, n  4, P  0.02) (Fig. 6C). We therefore tested our
treatment in a severe inﬂammatory setting by performing
cardiac transplantation in hyperglycemic NOD mice. Al-
though control mice promptly rejected heart transplants
(MST of 12 days), prolonged mATGCTLA4-Ig treatment
signiﬁcantly delayed heart cardiac allograft rejection (MST
of 21 days, n  4, P  0.03). Notably, in a purely
autoimmune setting, we conﬁrmed the ability of prolonged
mATGCTLA4-Ig treatment to strongly suppress autoim-
munity. NOD.SCID islets were transplanted under the
kidney capsule of diabetic NOD mice, and none of the
treated mice rejected their islet grafts (MST of 100 days,
n  5, P  0.002 vs. untreated) (Fig. 6D). The histopatho-
logic analysis of the graft at 100 days after transplantation
conﬁrmed that islets were fully preserved by our treatment
(IIS:1) (Fig. 6E).
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FIG. 5. IFN- production by splenocytes of transplanted mice was tested in response to donor-derived antigens (A) or BDC2.5 peptide (B), in an
ELISPOT assay. After transplantation, a robust antidonor antigen response was observed in untreated mice. This response was completely
prevented in the mATGCTLA4-Ig group (P < 0.05 vs. day 7 untreated) (A1). At day 14, IFN- production in response to donor-derived antigens
became signiﬁcant in the induction mATG group, whereas it was still prevented in the mATGCTLA4-Ig group (P < 0.05) (A2). Prolonged
mATGCTLA4-Ig prevented substantial IFN- production compared with induction mATGCTLA4-Ig at day 28 (P < 0.05) (A3). At day 56, the
IFN- response to alloantigen appeared to remain suppressed in the prolonged mATGCTLA4-Ig group (A4). Induction mATG reduced
autoimmune activation at day 7 (NS vs. normo) (B1), but not at day 14 (P < 0.05 vs. normo) (B2). The combination of mATG and CTLA4-Ig (either
induction only or prolonged mATG) completely abrogated the immune response to the autoantigen BDC2.5 (NS vs. normo) (B2–4). *P < 0.05.
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in newly hyperglycemic NOD mice. Considering the
effectiveness of prolonged mATGCTLA4-Ig in abrogating
the autoimmune response in a stringent model of alloge-
neic and syngeneic islet transplantation, we tested pro-
longed mATGCTLA4-Ig for its effect in reversing
established diabetes. Hyperglycemic NOD mice were
treated after 2 consecutive days of glucose measurements
240 mg/dl with prolonged mATGCTLA4-Ig. Notably,
normoglycemia was restored in 100% of treated mice (10
of 10 mice) (Fig. 7A). Reversal was, for the most part,
achieved rapidly: 7 mice reverted within the ﬁrst week
after the initiation of treatment; the other 3 mice reverted
in 2, 3, and 6 weeks, respectively. Mice that reverted at
later time points generally exhibited higher glucose levels
at the initiation of treatment. Normoglycemia was main-
tained for 60 days of follow-up (Fig. 7A). Mice in the
control group and the group treated with CTLA4-Ig alone
did not show any sign of restoration of normoglycemia
(Fig. 7B and C). On the contrary, 3 of 6 in the group treated
with prolonged mATG alone (Fig. 7D)a n d8o f1 2i nt h e
induction mATGCTLA4-Ig group stably reverted from
hyperglycemia (Fig. 7E).
Histologic analysis of the pancreas of treated mice was
performed 60 days after the onset of hyperglycemia. Islets
were predominantly free from inﬁltrates or were only
mildly inﬁltrated by lymphocytes, disposed around the
islets, with no invasive pattern. A major proportion of T
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FIG. 6. BALB/c skin was transplanted into NOD.SCID mice, which subsequently received (via adoptive transfer) 15  10
6 splenocytes from
normoglycemic or hyperglycemic untransplanted mice or from normoglycemic (not rejecting) or hyperglycemic (rejecting) transplanted mice
treated with prolonged mATGCTLA4-Ig at day 56 after transplantation. Skin rejection was slowed when adoptive transfer was performed with
splenocytes from treated transplanted mice compared with untreated untransplanted mice (normoglycemic vs. normoglycemic prolonged
mATGCTLA4-Ig P < 0.05; hyperglycemic vs. hyperglycemic prolonged mATGCTLA4-Ig; P < 0.05) (A). Therefore, in the same NOD.SCID mice,
we evaluated the onset of diabetes. Mice that received splenocytes by adoptive transfer from normoglycemic or hyperglycemic NOD mice
developed diabetes, as expected. However, the ability to transfer diabetes by splenocytes was completely abrogated in NOD mice treated with
prolonged mATG and CTLA4-Ig, either rejecting or not (untreated vs. prolonged mATGCTLA4-Ig; P < 0.001) (B). BALB/c hearts were
transplanted in NOD mice in a purely alloimmune setting; a prolongation of graft survival was observed in treated mice (untreated vs. prolonged
mATGCTLA4-Ig; P  0.017), similar results were obtained in hyperglycemic recipients (P  0.03) (C). NOD.SCID islets were transplanted into
hyperglycemic NOD mice; indeﬁnite survival was achieved in treated mice (untreated vs. prolonged mATGCTLA4-Ig; P  0.0018) (D).
NOD.SCID islet grafts harvested 100 days after transplantation in treated mice revealed completely preserved islet allografts with very few
inﬁltrating cells surrounding the islets (E1, H&E; E2, insulin; E3, glucagon; E4, B220; E5, CD3; E6, FoxP3). *P < 0.05. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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clearly positive (Fig. 7F). Islets from control hyperglyce-
mic mice appeared completely inﬁltrated with no appre-
ciable insulin staining (data not shown). Insulitis score
conﬁrmed that treatment had elicited reversal of islet
inﬁltration (Fig. 7G).
We then challenged splenocytes from treated mice 60
days after restoration of normoglycemia with BDC2.5
peptide and IGRP
(206–214) peptide to test the CD4 and CD8
autoimmune speciﬁc responses (32). IGRP
(206–214) peptide
is an islet peptide speciﬁc for some diabetogenic CD8

cells. IFN-	 production in response to either BDC2.5
peptide or IGRP
(206–214) peptide was similar in treated
mice and normoglycemic NOD mice, although it was
markedly increased in hyperglycemic mice (Fig. 7H). This
was paralleled by a Treg increase, both in the spleen (Fig.
7I) and pancreatic draining lymph nodes (PLN) (Fig. 7L),
as compared with either normo or hyperglycemic NOD
mice. On the contrary, the Teff frequency was reduced in
prolonged mATGCTLA4-Ig treated mice, both in the
spleen (Fig. 7M) and PLN (Fig. 7N). Quantiﬁcation of
autoreactive T cells by tetramers conﬁrmed the reduction
of autoimmunity obtained with the treatment (Fig. 7O).
DISCUSSION
Islet transplantation has been shown to be a viable alter-
native to chronic insulin injection; however, sustained
graft function has yet to be achieved (1,13,33,34). We used
a novel clinically relevant combination of mATG and
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FIG. 7. Diabetic mice were treated with prolonged mATGCTLA4-Ig the second day of glycemia >250 mg/dl. In 10 of 10 mice, diabetes was
reversed, and 7 of 10 reverted in the ﬁrst week. Although some ﬂuctuation was observed, a stable reversal of diabetes was observed in treated
mice (A). Untreated mice or CTLA4-Ig-treated mice never displayed reversal of hyperglycemia (B and C); 3 of 6 mice stably reverted in the
prolonged mATG group (D), whereas 8 of 12 reverted in the induction mATGCTLA4-Ig group. Histologic analysis showed a clear protection of
islets in treated mice, with an almost complete clearance of the lymphocyte inﬁltrate, which was conﬁned to the islet periphery. Notably, insulin
staining was well represented (F1, H&E; F2, insulin; F3, glucagon; F4, B220; F5, CD3; F6, FoxP3). Insulitis score conﬁrmed the reversal of the
inﬁltrate by the treatment (G). IFN- production by splenocytes was tested in response to BDC2.5 peptide and to IGRP
(206–214) peptide in
reverted mice at day 60 after treatment; prolonged mATGCTLA4-Ig completely suppressed the autoimmune response (NS vs. normo; P < 0.05
vs. hyper, n  3) (H). The proportion of Tregs was increased in treated mice (P < 0.05 vs. normo or hyper, n  3) (spleen: I; PLN: L), whereas
the Teff proportion was reduced (P < 0.05 vs. normo or hyper, n  3) (spleen: M; PLN: N); quantiﬁcation of autoreactive T cells by tetramer
staining conﬁrmed the reduction of autoimmunity in prolonged mATGCTLA4-Ig treated mice (P < 0.05 vs. hyper, n  3) (O). *P < 0.05. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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mune responses and to enhance long-term graft survival in
a stringent model of allogeneic islet transplantation in
hyperglycemic NOD mice. Notably, although long-term
islet function was lost, there were no signs of recurrence
of autoimmunity. This ﬁnding, together with the fact that
both ATG and CTLA4-Ig are readily available for clinical
use, indicates this combination is a novel candidate treat-
ment for autoimmune type 1 diabetes (25,27,35).
The efﬁcacy of the combination of ATG and CTLA4-Ig
appears to be related to the immunoregulatory properties
of each drug alone, which have a synergistic effect when
administered together. The mATG is a depleting agent
with the potential for immunomodulatory activity; indeed,
we conﬁrmed an increase in Tregs after mATG treatment.
However, depleting agents are a double-edged sword; that
is, although they reduce the number of alloreactive T cells,
they can also activate the immune system through the
process of homeostatic proliferation (19). In our model,
mATG-mediated depletion is also followed by a rapid
T-cell recovery associated with an increase in Teffs and a
Th1 peripheral cytokine storm. The technique of using a
combination of CTLA4-Ig and mATG rather than mATG
alone has the potential to overcome this effect. Though
CTLA4-Ig per se has little impact on allo- and autoimmu-
nity, its effect in combination with mATG is striking.
Although CTLA4-Ig likely exerts immunoregulatory ef-
fects, we propose that most of the impact on graft survival
is related to inhibition of homeostatic proliferation, as the
recovery of the T-cell curve is in fact slowed, which may
be related to an inhibition of the release of proliferative
cytokines such as IL-7 and IL-15. Conversely, CTLA4-Ig
may also somehow reduce Treg percentage after mATG
treatment, conﬁrming the role of CD28 in Treg homeosta-
sis (24,36). The net balance of these effects is most likely
in favor of a Treg increase and a regulatory immune
response proﬁle. Prolonged mATGCTLA4-Ig treatment
has been shown to be superior to induction mATG
CTLA4-Ig treatment in terms of graft survival; although it is
possible that some of the enhanced effect may be mediated
by further T-cell depletion, data suggest an active modu-
lation of the immune system during T-cell reconstitution.
In fact, compared with induction mATGCTLA4 treat-
ment, prolonged mATGCTLA4-Ig treatment elicited an
increase in the proportion of Tregs, a reduction in IFN-	,
and a preservation of IL-4 production versus both allo- and
autoimmune antigens.
Immunologic analysis also revealed a complete suppres-
sion of autoimmunity in prolonged mATGCTLA4-Ig-
treated mice. Speciﬁcally, IFN-	 production of splenocytes
extracted from treated mice and challenged with the
islet-derived BDC2.5 peptide was markedly if not com-
pletely abrogated. The adoptive transfer of splenocytes
from nonrejecting- and rejecting-treated mice into NOD.
SCID did not transfer diabetes. Syngeneic islet grafts
survived indeﬁnitely in 100% of transplanted mice, and
newly hyperglycemic NOD mice, when treated with pro-
longed mATGCTLA4-Ig, reverted to normoglycemia in
100% of the mice and showed a complete reversal of CD4
and CD8 autoimmune responses.
With regard to alloimmunity, prolonged mATGCTLA4-Ig
treatment appears to exert a profound immunosuppres-
sive effect, although it may not be sufﬁcient in the long
term to prevent graft loss. In fact, although in vitro
experiments demonstrated that the IFN-	 response is
suppressed, in adoptive transfer experiments, splenocytes
from treated animals retained the potential to transfer the
ability to reject donor-derived skin transplants. In accor-
dance with this observation, in a model that assesses the
alloantigen response alone, cardiac allografts were even-
tually rejected.
These ﬁndings suggest that ATG can be used not only as
an induction therapy, but also as a prolonged treatment.
Interestingly, its combination with CTLA4-Ig is shown to
reduce postdepletion homeostatic proliferation. Both allo-
and autoimmune responses were affected; in particular,
the autoimmune response was completely abrogated with
100% diabetes reversal and 100% indeﬁnite survival of
syngeneic islet grafts. We submit the use of prolonged
mATGCTLA4-Ig as a major breakthrough in the ﬁeld of
type 1 diabetes treatment.
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